Background/Aims: Retinoic acid receptor beta (RAR beta) is a retinoic acid receptor gene that has been shown to play key roles during multiple cancer processes, including cell proliferation, apoptosis, migration and invasion. Numerous studies have found that methylation of the RAR beta promoter contributed to the occurrence and development of malignant tumors. However, the connection between RAR beta promoter methylation and prostate cancer (PCa) remains unknown. This meta-analysis evaluated the clinical significance of RAR beta promoter methylation in PCa. Materials and Methods: We searched all published records relevant to RAR beta and PCa in a series of databases, including PubMed, Embase, Cochrane Library, ISI Web of Science and CNKI. The rates of RAR beta promoter methylation in the PCa and control groups (including benign prostatic hyperplasia and normal prostate tissues) were summarized. In addition, we evaluated the source region of available samples and the methods used to detect methylation. To compare the incidence and variation in RAR beta promoter methylation in PCa and non-PCa tissues, the odds ratio (OR) and 95% confidence interval (CI) were calculated accordingly. All the data were analyzed with the statistical software STATA 12.0. Results: Based on the inclusion and exclusion criteria, 15 articles assessing 1,339 samples were further analyzed. These data showed that the RAR beta promoter methylation rates in PCa tissues were significantly higher than the rates in the non-PCa group (OR=21.65, 95% CI: 9.27-50.57). Subgroup analysis according to the source region of samples showed that heterogeneity in Asia was small (I 2 =0.0%, P=0.430). Additional subgroup analysis based on the method used to detect RAR beta promoter methylation showed that the heterogeneity
Introduction
Prostate cancer (PCa) predominantly affects male patients and is associated with considerable morbidity and mortality. According to data from 2016, there were 161, 360 new PCa cases in the United States, and 26, 730 patients died from PCa [1] . The molecular mechanisms involved in malignant PCa progression include multiple sequential genetic and epigenetic events [2] . Prostate-specific antigen (PSA) and/or rectal digital examination are the main methods for diagnosing PCa [3] . However, PSA is specific to prostate tissue, not PCa [4] , and two large trials have suggested that the net benefit of PSA measurement is marginal at best, whereas the harms are substantial [5] . Controversy also remains regarding whether current screening methods can be applied to the early diagnosis and treatment of PCa [6] .
A growing body of evidence [7] [8] [9] [10] [11] [12] has shown that epigenetic alterations show promise for future translational applications in molecular pathology detection and prognostic evaluation. DNA methylation is an epigenetic event with an important role regulating gene expression. In particular, hypermethylation of the promoter region often leads to transcriptional repression and causes transcriptional silencing in malignant tumors, including PCa [13] . Promoters have critical functions in PCa progression and can differentiate PCa from benign alterations [14] . Retinoic acid, the metabolite of vitamin A [15] , inhibits tumor growth by interacting with its receptor, especially retinoic acid receptor beta (RAR beta) [16, 17] . RAR beta has two different subtypes that express different RNA transcripts [18] , with the RAR beta-2 isoform predominantly expressed in most human cells. The methylation rate of the RAR beta-2 isoform promoter in patients with initial PCa and HIPC (hormone-independent PCa) was reported to be 79% and 90%, respectively, although normal prostate and benign prostatic hyperplasia (BPH) tissues were not analyzed [2] .
Many records have reported that aberrant RAR beta promoter methylation occurs in hepatocellular carcinoma (HCC) [19] , breast cancer [20] and non-small-cell lung carcinoma (NSCLC) [21] . Nevertheless, relevant analyses examining the association between RAR beta promoter methylation and PCa are lacking. Thus, we summarized all relevant published articles and performed further analysis. Changes in RAR beta promoter methylation occurred in the early stages of PCa [22] and have been analyzed using a PCR-based detection technique, which shows high sensitivity and could be ideal for biomarker detection. Therefore, our meta-analysis may provide additional information identifying potential biomarkers for early PCa diagnosis.
Materials and Methods

Retrieval strategy
We searched available studies up to March 2017 in the PubMed, Embase, Cochrane Library, ISI Web of Science and CNKI databases using the corresponding combination of subject words and free words: "prostate cancer," "prostatic neoplasms," [Mesh] "retinoic acid receptor beta" and "methylation". In addition, the references of the included articles and reviews were also retrieved.
Selection criteria of eligible studies
The following inclusion criteria were applied: 1. Published original literature examining the relationship between RAR beta promoter methylation and PCa. 2. The purpose of the study and the statistical methods were similar, and the data were complete. 3. Methylation of the RAR beta promoter was detected using PCRbased methods. 4. All the patients met the diagnostic criteria for PCa, and all the studies were independent case-control studies. 5. An odds ratio (OR) with a 95% confidential interval (CI) was reported.
Exclusion criteria of alternative studies
The following exclusion criteria were applied: 1. The study was an animal study. 2. The study was a cell line study. 3. The study was a review or meta-analysis. 4 . No data on the relationship between RAR beta promoter methylation and PCa were provided. 5. There were defects in the study design or the data were incomplete.
Literature screening
According to the information extraction protocol, two researchers searched the literature independently. Then, the title and abstracts of each available study were evaluated based on the inclusion/ exclusion criteria. If the title and abstracts were not controversial and could be evaluated, we chose to read the full text. Throughout the search process, a third researcher had the right to make the ultimate decision in cases of disagreement.
Data extraction
The data extraction was performed independently by 2 researchers, and any disagreement was resolved through panel discussions. The extracted information included the following: first author, publication year, source region, study type, the RAR beta promoter methylation rate in the PCa group and the control group (normal prostate tissue or BPH), the methods of methylation detection, and the OR with 95% CI.
Statistical analyses
All the data were analyzed using the statistical software STATA 12.0. The OR was expressed with the 95% CI. If the OR was more than 1 and the 95% CI did not overlap, it was concluded that RAR beta promoter methylation increased PCa risk. If the OR was less than 1, it was concluded that RAR beta promoter methylation decreased PCa risk. The test of heterogeneity was performed with a χ 2 test and an I 2 test. If there was no statistical heterogeneity between the studies (P=0.10 and I 2 <50%), a fixed effects model was applied to the meta-analysis. Otherwise, a random effects model was used. In addition, subgroup analyses were stratified according to the patient source region and the method used to detect methylation to explore the differences and potential sources of heterogeneity. In the presence of heterogeneity, a sensitivity analysis was performed by removing the included studies one by one to evaluate whether a specific omission affected the overall outcome. Funnel plots were used to evaluate publication bias if more than 9 records were included. A P value less than 0.05 was considered statistically significant.
Results
The study inclusion procedure and study characteristics Based on the retrieval strategy, 42 articles were included after the initial screening. According to further investigation, we found that 1 record was an editorial [23] and another was a meta-analysis [24] . After screening the full text, it was discovered that 7 articles focused on cell lines, 11 articles lacked complete data, and 7 articles were not case-control studies, and these were excluded from this study. Finally, 15 records, including 1, 339 samples, were deemed eligible [2, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] excluded studies and the characteristics of the studies included in the meta-analysis are shown in Fig. 1 and Table 1 .
The quality of case-control studies as assessed by the Newcastle-Ottawa Scale (NOS)
We used the Newcastle-Ottawa Scale (NOS) to assess the quality of the 15 included records, as recommended by the Cochrane Non-Randomized Studies Methods Working Group [39] . The table consists of 3 blocks, including selection, comparability and assessment of the outcome, for a total of 9 entries. The NOS uses a semi-quantitative star system to evaluate study quality; 9 stars corresponds to "perfect", and more than 5 stars indicates "high-quality". All the details are shown in Table 2 . 
RAR beta promoter methylation differences in PCa and non-PCa tissues
As shown in Fig. 2 , 15 studies reported the relationship between RAR beta promoter methylation and PCa risk. Because significant heterogeneity between studies was identified (I 2 =71.80%, P=0.000), a random effects model was used for the meta-analysis. The ultimate outcome suggested that the methylation rate of the RAR beta promoter in PCa tissues was significantly higher than that of the nonPCa group (OR=21.65, 95% CI: 9.27-50.57). In addition, RAR beta promoter methylation increased PCa risk by 21.65-fold. To explore the source of the significant heterogeneity, a subgroup analysis of patient source region and methylation detection method was performed. As shown in Fig. 3 , the heterogeneity of the metaanalysis in Asia was small (I 2 =0.0%, P=0.430). Further subgroup analysis according to RAR beta promoter methylation detection method showed that the heterogeneity from MSP (methylationspecific PCR) was relatively small (I 2 =11.3%, P=0.343) (Fig. 4) . The subgroup analysis results indicated that the heterogeneity of the studies might be caused by regional differences in disease incidence or differences in the methylation detection methods.
The analysis of sensitivity and publication bias
In addition, due to the presence of heterogeneity, a sensitivity analysis was performed by removing the included studies one by one to assess whether a specific omission affected the overall outcome. As shown in Fig. 5 , the results were not altered significantly after excluding any of the 15 articles, demonstrating the stability of this meta-analysis. Moreover, a funnel 
plot was used to test the potential publication bias of the included studies. As shown in Fig.  6 , the scatter of the points in the funnel plot was asymmetric, suggesting publication bias. Thus, the filled funnel plot method was applied to adjust the bias and calculate the number of unpublished studies that may have led to asymmetry (Fig. 7) . The results showed that the adjusted OR (OR=7.97, 95% CI: 3.33-19.10, P=0.000) was similar to that of the previous summary. Therefore, the sensitivity analysis and publication bias tests demonstrated the stability of the ultimate conclusion of this meta-analysis.
Discussion
PCa is one of the most common malignant tumors and a major public health problem, and its incidence is likely to increase as the population ages [40] . Because the specific molecular mechanisms of PCa remain unclear and current PCa screening methods cannot precisely differentiate malignant cancers from begin prostatic hyperplasia [41] , it is necessary to find novel biomarkers for better screening and fast, accurate PCa diagnosis. Researchers [42] [43] [44] have increasingly realized that epigenetic alterations are involved in the early stages of PCa development, even in precancerous lesions.
Methylation of the RAR beta promoter is an epigenetic biomarker that has been extensively studied in PCa. This alteration has been detected in many studies [25, 28, 34, 38] , although some have reported controversial results [27, 29, 36] . Cho, NY et al [26] . examined the RAR beta promoter methylation level in 179 cases of prostate adenocarcinoma and 30 cases of BPH using MSP. These authors found that the gene methylation frequencies in PCa were significantly higher than those in BPH (123/179, 1/30), indicating that RAR beta promoter methylation was cancer-related (OR=63.70, 95% CI: 8.46-479.37). However, Hanson JA et al [29] . did not observe obvious differences in RAR beta promoter methylation between tumor epithelium and histologically normal-appearing epithelium (in all five patients and in four of five samples, respectively). Thus, the relationship between RAR beta promoter methylation and PCa warrants further research.
Our meta-analysis showed that RAR beta promoter methylation levels were significantly higher in PCa patients than in non-PCa patients (OR=21.65, 95% CI: 9.27-50.57, P=0.000), suggesting a potential role for this type of methylation in the malignant progression of PCa. We also performed subgroup analysis to explore the potential impact of the source region and methylation detection method on the association between RAR beta promoter methylation and PCa. The outcomes showed the following regional RAR beta promoter methylation rates: Europe (OR=32.53, 95% CI: 2.37-446.12, P=0.006), Asia (OR=28.53, 95% CI: 12.83-63.45, P=0.430), and North America (OR=12.10, 95% CI: 3.85-38.05, P=0.003). Of note, the correlation in Europe was apparently higher than that in Asia and North America, and this difference may be due to genetic background, environment, and sample size. Because the RAR beta promoter methylation levels were detected using different methods, we also performed a subgroup analysis according to methylation detection method to identify potential sources of heterogeneity and differences between studies. The results showed that the heterogeneity detected by MSP was relatively small (I 2 =11.3%, P=0.343), indicating that some of the heterogeneity between studies may be due to differences in the methylation detection methods used. The sensitivity analysis and publication bias tests demonstrated the stability of the ultimate conclusion in this meta-analysis.
In brief, the RAR beta gene is a major PCa susceptibility gene. A study by Cho et al. from 2009 identified more than 50 genes inactivated by promoter CpG island hypermethylation in PCa, and the most relevant other than RAR beta include GSTP1, RASSF1, and p16 [24] . Regarding the relationship between RAR beta and other genes, Moison C et al [45] . found that hypermethylation of the RAR beta promoter was positively correlated with H3K27me3 enrichment. Nevertheless, Zhang J et al [2] . demonstrated that the promoter methylation levels of TIG1 (tazarotene-induced gene 1, also known as retinoid acid receptor-responsive 1 gene) and RAR beta were positively correlated (r=0.35; P=0.017). However, the specific Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry mechanism of this interaction remains unclear, and whether the same CpGs were analyzed in the selected articles is worth future studies. Moreover, Roupre M et al [46] . observed that men with advanced PCa and biochemical recurrence experienced a significant increase in RAR beta promoter hypermethylation between the initial diagnosis (first blood sample) and the time to progression (second blood sample), with the highest methylation frequencies observed in PCa patients compared with those in age-matched controls. In this study, all the data were from clinical research tissue samples. Thus, data concerning RAR beta promoter methylation in cell lines are insufficient, especially in stem cell lines that would likely support cancer progression. Additional research is required to explore the specific mechanisms concerning RAR beta promoter methylation in cell lines and the interaction between RAR beta and other relevant genes.
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